ASCT2A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial
Cook, G Williams, C Cairns, D Hockaday, A Cavenagh, J Snowden, J Parrish, C Yong, K Cavet, James Hunter, H
Cook, G
Williams, C
Cairns, D
Hockaday, A
Cavenagh, J
Snowden, J
Parrish, C
Yong, K
Cavet, James
Hunter, H
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2015
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
ASCT2A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial. 2015, 126: Blood